AGIO:NGS-Agios Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 34.14

Change

+0.60 (+1.79)%

Market Cap

USD 2.60B

Volume

0.52M

Analyst Target

USD 65.45
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B

ETFs Containing AGIO

WDNA:LSE WisdomTree BioRevolution .. 2.44 % 0.00 %

+0.13 (+0%)

N/A
WBIO:LSE WisdomTree BioRevolution .. 2.29 % 0.00 %

+10.20 (+0%)

USD 3.58M
WDNA 2.27 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.26 % 0.00 %

-0.03 (0%)

USD 2.77M
ETHO Amplify ETF Trust 0.52 % 0.45 %

+0.01 (+0%)

USD 0.18B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 53.30% 83% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.30% 83% B 91% A-
Trailing 12 Months  
Capital Gain 34.36% 79% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.36% 79% B- 80% B-
Trailing 5 Years  
Capital Gain -31.36% 63% D 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.36% 63% D 31% F
Average Annual (5 Year Horizon)  
Capital Gain -6.79% 50% F 30% F
Dividend Return -6.79% 50% F 29% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.90% 89% A- 65% D
Risk Adjusted Return -24.35% 43% F 29% F
Market Capitalization 2.60B 88% B+ 79% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.80 73% 93%
Price/Book Ratio 2.05 61% 47%
Price / Cash Flow Ratio -6.33 71% 78%
Price/Free Cash Flow Ratio -2.48 61% 70%
Management Effectiveness  
Return on Equity -39.61% 75% 36%
Return on Invested Capital -40.95% 64% 25%
Return on Assets -24.55% 64% 21%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector